Multidisciplinary Evaluation denied as experimental or investigational by Humana?

Humana's specific coverage criteria for multidisciplinary evaluation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies a Multidisciplinary Evaluation as Experimental — and Why That Label Is Wrong

A denial coding a multidisciplinary evaluation as 'experimental' or 'investigational' is highly unusual for a service type that is broadly recognized as standard of care across multiple medical specialties. This denial warrants careful scrutiny: it may reflect an incorrect procedure code, a plan exclusion written more broadly than intended, or an internal policy that contradicts established clinical consensus.

## Why This Denial Is Strongly Appealable

Multidisciplinary evaluation panels — whether for complex pain, oncology, neurodevelopmental conditions, cardiac conditions, or other complex presentations — are endorsed as standard of care by numerous specialty societies. Humana's own coverage policy almost certainly does not exclude standard multidisciplinary evaluations for your specific indication. If the denial rests on an 'experimental' classification, the appeal should document the consensus standard of care and request that Humana identify the specific criteria under which it classified the service as experimental.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Request the specific criteria and clinical evidence Humana used to classify this service as experimental. You have the right to a full-and-fair review and to submit a clinical rebuttal.
• External review (ACA §2719): If the internal appeal is denied, request IRO review within approximately four months of the original denial. Expedited review is available when delay creates serious health risk.

## Appeal Timeline

1. Request the full claim file, the clinical criteria used, and the specific evidence Humana relied on for the 'experimental' classification. 2. Obtain the applicable specialty guideline organization's endorsement of multidisciplinary evaluation for the patient's condition. 3. Submit the internal appeal with the documentation below. 4. If denied, file for external IRO review within the statutory window.

## Documentation to Gather

• Standard-of-care evidence: A reference to the relevant specialty guideline organization (e.g., the applicable NCCN, ACC, AAN, or other guideline body) that recommends or endorses multidisciplinary evaluation for the patient's diagnosis — cite the organization, not statistics.
• Diagnosis and complexity: Chart documentation establishing the clinical complexity that makes multidisciplinary evaluation appropriate.
• Ordering provider letter: A letter explaining the clinical rationale and stating that multidisciplinary evaluation is the recognized standard of care for this patient's presentation.
• Request for Humana's criteria: A written demand that Humana provide the specific evidence it used to classify the service as experimental, and the published date of that classification.

## Criteria-Mapping Structure

Build a two-column rebuttal: left column states Humana's experimental classification language; right column cites the guideline organization's endorsement and the chart facts supporting clinical necessity. Submit alongside the ordering provider's letter.